A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function

A Study Investigating the Pharmacokinetic Properties, Safety and Tolerability of NNC0487-0111 in Participants With Various Degrees of Hepatic Impairment and Participants With Normal Hepatic Function

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07587710

Enrollment

Registered

2026-05-14

Start date

2026-05-13

Completion date

2027-12-01

Last updated

2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight, Obesity

Brief summary

The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people with normal liver function.

Interventions

DRUGNNC0487-0111

NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors in a skinfold in the thigh.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Male or female (sex at birth). * Age 18-80 years (both inclusive) at the time of signing informed consent. * Participants with stable hepatic impairment classified as Child-Pugh grade A, B or C as assessed by the investigator. Stable hepatic impairment is defined as no clinically significant change in disease status, as judged by the investigator.

Exclusion criteria

* Known or suspected hypersensitivity to study intervention(s) or related products. * Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.

Design outcomes

Primary

Measure	Time frame	Description
AUC0-∞: The area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose	From pre-dose on Day 1 up to Day 28	Measured as hours\nanomole per liter (nmol\h/L)

Secondary

Measure	Time frame	Description
Cmax: Maximum observed plasma NNC0487-0111 concentration after a single dose	From pre-dose on Day 1 until Day 5	Measured as nanomoles per liter (nmol/L)
tmax: Time to maximum observed plasma NNC0487-0111 concentration after a single dose	From pre-dose on Day 1 until Day 5	Measured as hour
t½,: Terminal half-life for NNC0487-0111 after a single dose	From pre-dose on Day 1 up to Day 28	Measured as hour
Vz/F: Apparent volume of distribution of NNC0487-0111 after a single dose	From pre-dose on Day 1 up to Day 28	Liter
CL/F: Apparent clearance of NNC0487-0111 after a single dose	From pre-dose on Day 1 up to Day 28	Measured as liter per hour (L/h)
Number of treatment emergent adverse events (TEAEs)	From pre-dose on Day 1 up to Day 28	Measured as number of events

Countries

Slovakia

Contacts

CONTACTNovo Nordisk

clinicaltrials@novonordisk.com(+1) 866-867-7178

STUDY_DIRECTORClinical Transparency (dept. 2834)

Novo Nordisk A/S

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026